Literature DB >> 14640042

Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.

Per Westermark1, Joakim Bergström, Alan Solomon, Charles Murphy, Knut Sletten.   

Abstract

Senile systemic amyloidosis (SSA) is a prevalent disease affecting the elderly and results from the pathologic deposition, predominantly in the heart, of unmutated (wild-type) transthyretin (TTR) molecules. This disorder differs from the familial TTR-associated amyloidoses that generally occur in a younger population and involves peripheral nerves but, notably, the deposits contain mutated (variant) forms of the amyloidogenic precursor protein. To gain further insight into the clinicopathologic features and pathogenesis of SSA, we have reviewed the post-mortem findings of 33 Swedish individuals (27 men, 6 women) who had pronounced cardiac amyloid disease. Additionally, in all cases there were amyloid deposits within the lungs. Seven of the patients were uremic, possibly due to fibrillar deposits in the renal medullary papilla. In contrast to other systemic amyloidoses, none of the 33 had more than minute congophilic material in the renal cortex, liver, or spleen. We have also analyzed the chemical composition of fibrils extracted from myocardium and have found that the protein consisted mainly of C-terminal fragments of TTR starting at positions 46, 49, and 52. Furthermore, we identified through antigenic mapping, an epitope present on the H strand of fibrillar, but not normal, plasma TTR molecules indicating that this strand is exposed in fibrils. We suggest that ATTR fibrils may develop both from full-length TTR and from C-terminal TTR fragments and that the N-terminal part is not necessary for the fibril integrity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14640042

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  36 in total

1.  Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).

Authors:  Jacquelyn L Sikora; Mark W Logue; Gloria G Chan; Brian H Spencer; Tatiana B Prokaeva; Clinton T Baldwin; David C Seldin; Lawreen H Connors
Journal:  Hum Genet       Date:  2014-11-04       Impact factor: 4.132

Review 2.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

3.  Discordant results between biochemical and molecular transthyretin assays: lessons learned from a unique testing algorithm at the Mayo Clinic.

Authors:  Honey V Reddi; Brittany C Thomas; Kurt S Willkomm; Matthew J Ferber; Kandelaria M Rumilla; Kimiyo M Raymond; John F O'Brien; W Edward Highsmith
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

4.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

Authors:  Lorena Saelices; Kevin Chung; Ji H Lee; Whitaker Cohn; Julian P Whitelegge; Merrill D Benson; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

5.  A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Authors:  Sungwook Choi; Natàlia Reixach; Stephen Connelly; Steven M Johnson; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2010-02-03       Impact factor: 15.419

6.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

7.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

Review 8.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

9.  Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.

Authors:  Steven M Johnson; Stephen Connelly; Ian A Wilson; Jeffery W Kelly
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

10.  Human placental transthyretin in fetal growth restriction in combination with preeclampsia and the HELLP syndrome.

Authors:  Arrigo Fruscalzo; R Schmitz; W Klockenbusch; G Köhler; A P Londero; M Siwetz; B Huppertz
Journal:  Histochem Cell Biol       Date:  2012-07-31       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.